CORDIS
EU research results

CORDIS

English EN
Development of methodology for alternative testing strategies for the assessment of the toxicological profile of nanoparticles used in medical diagnostics

Development of methodology for alternative testing strategies for the assessment of the toxicological profile of nanoparticles used in medical diagnostics

Objective

Nanoparticles (NP) have unique, potentially beneficial properties, but their possible impact on human health has not been adequately assessed. The main goal of this proposal is to develop alternative high-throughput testing strategies using in vitro and in silico methods to assess the toxicological profile of NP used in medical diagnostics. Our specific aims are to: 1. Define NP properties and fully characterize NP to be used 2. Study NP interactions with molecules, cells and organs and develop in vitro methods to study the toxicological potential of NP 3. Validate in vitro findings in short-term in vivo models and study particle effects in animals and (ex vivo) in humans to assess individual susceptibility to NP 4. Develop in silico models of NP interactions Experimental work is structured in 4 WPs to address NP characterisation and key elements in evaluation of NP uptake, exposure and toxicology. NANOTEST integrates the investigation of toxicological properties and effects of NP in several target systems by developing a battery of in vitro assays using cell cultures, organotypic cell culture and small organ fragments (ex vivo) derived from different biological systems; blood, vascular system, liver, lung, placenta, digestive and central nervous systems. As NP action is likely to involve oxidative stress we will focus on the cross-cutting areas of inflammation, cellular toxicity, immunotoxicity, genotoxicity and related endpoints. Following development of SOP and generation of a common database and in parallel with in silico assays (QSAR, PBPK modelling), NanoTest will evaluate toxic effects and interactions of NP used in nanomedicine. Results will be validated in an experimental ethically approved in vivo model. The most advanced and standardised techniques will be adapted for automation and prepared for validation by ECVAM. Separate WPs will be dedicated to dissemination and to effective administrative and scientific management.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

NORSK INSTITUTT FOR LUFTFORSKNING STIFTELSE

Address

Instituttveien 18
2027 Kjeller

Norway

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 578 430

Administrative Contact

Maria Dusinska (Dr.)

Participants (11)

Sort alphabetically

Sort by EU Contribution

Expand all

INSTITUTE OF OCCUPATIONAL MEDICINE

United Kingdom

EU Contribution

€ 130 593

CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS

Switzerland

EU Contribution

€ 215 750

UNIVERSITE PARIS DIDEROT - PARIS 7

France

EU Contribution

€ 193 250

University Hospitals Bristol NHS Foundation Trust

United Kingdom

EU Contribution

€ 188 196

JRC -JOINT RESEARCH CENTRE- EUROPEAN COMMISSION

Belgium

EU Contribution

€ 463 842

"NATIONAL CENTER FOR SCIENTIFIC RESEARCH ""DEMOKRITOS"""

Greece

EU Contribution

€ 150 050

SLOVENSKA ZDRAVOTNICKA UNIVERZITA V BRATISLAVE

Slovakia

EU Contribution

€ 339 750

KOBENHAVNS UNIVERSITET

Denmark

EU Contribution

€ 188 670

ADVANCELL ADVANCED IN VITRO CELL TECHNOLOGIES S.A.

Spain

EU Contribution

€ 308 508,99

UNIVERSITA CA' FOSCARI VENEZIA

Italy

EU Contribution

€ 158 520

ACONDICIONAMIENTO TARRASENSE ASSOCIACION

Spain

EU Contribution

€ 78 823,01

Project information

Grant agreement ID: 201335

Status

Closed project

  • Start date

    1 April 2008

  • End date

    31 March 2012

Funded under:

FP7-HEALTH

  • Overall budget:

    € 3 933 271,01

  • EU contribution

    € 2 994 383

Coordinated by:

NORSK INSTITUTT FOR LUFTFORSKNING STIFTELSE

Norway